Name: UMIN ID:
Unique ID issued by UMIN | UMIN000010319 |
---|---|
Receipt number | R000012078 |
Scientific Title | Phase II study of TS-1+Irinotecan+Bevacizumab as second-line treatment in patients with metastatic colorectal cancer refractory to fluoronated pyrimidine, oxaliplatin, and cetuximab therapy |
Date of disclosure of the study information | 2013/03/26 |
Last modified on | 2016/11/24 15:00:59 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2013/03/26 17:22:13 | ||
2 | Update | 2016/11/24 13:15:13 | Key inclusion criteria |
|
3 | Update | 2016/11/24 14:50:11 | Last name of lead principal investigator Last name of lead principal investigator Organization Organization Division name Division name Address Address TEL Last name of contact person Last name of contact person Organization Organization Division name Division name Address Address TEL Organization Organization Division name Division name Address Address TEL Name of primary person or sponsor Institute Organization Organization Address1 |
|
4 | Update | 2016/11/24 14:50:43 | Recruitment status Publication of results |
|
5 | Update | 2016/11/24 15:00:59 | Recruitment status |